PUBLISHED ON: June 26, 2009 | Duration: 3 min, 42 sec
Ranjit Kapadia, VP of institutional research at HDFC Securities, said at this moment it is difficult to quantify the hit Sun Pharma is likely to get after US FDA seized drugs at its US subsidiary.
